Collegium CEO Michael Heffernan Named EY Entrepreneur of the Year

27 June, 2016

CANTON, Mass., June 27, 2016 (GLOBE NEWSWIRE) — EY announced that Collegium’s CEO, Michael Heffernan, received the EY Entrepreneur of the Year® 2016 Award in the Life Sciences and Healthcare category in New England. This year marks the 30th anniversary of the EY Entrepreneur of the Year Award program. The award recognizes outstanding entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance, and personal commitment to their businesses and communities. Winners were selected by an independent panel of judges, and the award was presented at a special gala event at the Marriott Copley Place on June 23, 2016.

 
Related News
Collegium Announces Commercial Launch of Xtampza® ER
06.20.16
CANTON, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the commercial launch of Xtampza® ER (oxycodone) extended-release (ER) capsules in the United States. Xtampza ER was approved by the U.S. Food and Drug Administration (FDA) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Read Full Release
Collegium Announces Publication of Data on the In Vitro Assessment of IV Abuse of Xtampza ER in Journal of Opioid Management
03.03.16
CANTON, Mass., March 03, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from a laboratory-based extraction, injection and syringeability study for Xtampza® ER compared to other marketed opioid analgesics in peer-reviewed Journal of Opioid Management. The publication is titled, “In Vitro Assessment of the Potential for Abuse via the Intravenous Route of Oxycodone DETERx® Microspheres.” Read Full Release
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
11.09.15
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announces that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules. Read Full Release